TickerTalks
Browse all tickers →
TickerTalks›$RLAY
RLRLAY

Relay Therapeutics, Inc.

$RLAY·$3.8B·Biotechnology·Healthcare
$18.36+3.8%YTD+119.9%1Y+253.8%
Price updated 4h ago·X counts updated 2d ago
RLRLAY
$RLAYRelay Therapeutics, Inc.
$18.36+3.79%90 posts1×
AI analysisFundamentalsVoices on X
Loading…

On X

The complete picture of $RLAY on X — how loud the conversation is right now, how it has trended over the last two weeks, and which way the crowd is leaning.

90X posts · last 7 days
Sep 12Sep 27
Chatter Meter
1×
QuietNormal · 1×Loud

How loud $RLAY's conversation on X is versus its own normal — 1× is typical, higher means busier. Right now it's about its usual level, louder than 82% of tracked names.

Bullish sentimentAI analysisGenerated by AI from underlying data7 posts analyzed · as of 2026-08-14

Relay Therapeutics is strongly bullish. Citizens PT raised to $26 from $21 (Market Outperform) and Guggenheim PT $26 (Buy) on zovega Ph3 execution, YE Ph3 enrollment update expected, pooled ~40% of Ph3-size data giving confidence. Perceptive Advisors increased holding 44.66% to 6.4% ownership. YTD +143.47%, from $3 to $20.

Read what X is saying about $RLAY

  • Bullish vs bearish call — with the AI summary of the day's posts
  • Divergence flag when the top-engagement posts argue the other side
  • How loud the conversation is versus this ticker's own normal
Free, forever. No credit card.

AI verdictAI analysisGenerated by AI from underlying data

TickerTalks' own read on what's driving $RLAY — fundamentals, momentum, or an event — and whether it agrees with the X crowd.

Hinges on a big eventEvent coming upAI verdict · as of 2026-09-28

A known event soon (earnings, a ruling, etc.) will likely decide the next move.

Zovega Ph3 setup with Perceptive Advisors ripping to 6.4% and PTs at $26 — but a $213M raise just happened.

The setup is real and the smart money is engaged; the print in front of the Ph3 tape is what matters.

  • Citizens PT raised to $26 (Market Outperform); Guggenheim Buy at $26; both riding zovega Ph3 execution + YE enrollment read.
  • Perceptive Advisors upped holding 44.66% to 6.4% — a specialist biotech fund doubling in.
  • +112% YTD, +299% t12m, 78% of 52w range; -9% vs 50-day, +27% vs 200-day — a coiled tape.
  • 8/6 prospectus supplement: 16.0M shares at $0.001 face, ~$213M raised. Perceptive-tier funding, but dilution is real.
  • Losses ongoing: FY26 est EPS -$1.60, revenue $10.5M — this is a pipeline stock, not a business.
  • Beta 1.70 — expect two-way volatility on any Ph3 headline.

Watch 11/5 print for Ph3 enrollment update and any interim futility signal disclosure.

Agrees with X sentimentBulls have the setup right; what the chatter doesn't dwell on is that the $213M raise is what got them to Ph3 completion — appropriate but material to future dilution risk.

What to watch: 11/5 earnings, YE enrollment milestone, Ph3 interim readout, and any partnership on zovega commercial rights.

On the calendar: 2026-11-05

Read the AI verdict on $RLAY

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • Whether TickerTalks' read agrees with or diverges from the X crowd
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Develops kinase inhibitor cancer drugs using protein motion simulation to design precision oncology therapies.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $RLAY.

Biotechnology · Healthcare

No material change from last week — mRNA oncology platform remains the structural driver.

What this means for $RLAY

Partial — Develops kinase inhibitor cancer drugs using protein motion simulation to design precision oncology therapies.

Top industry ETF

$IBBiShares Biotechnology ETF
+24.4%YTD
+48.0%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-8.9How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-44.0%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-27.8%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-9.0%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
221.6Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-43.9%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
89.7%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.0Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 6, 2026$-0.41$-0.39-4.8%
Q1 2026May 5, 2026$-0.41$-0.35-17.1%
Q4 2025Feb 26, 2026$-0.32$-0.38+15.8%
Q3 2025Nov 6, 2025$-0.43$-0.39-10.3%
Next earningsThu, Nov 5·consensus EPS $-0.40

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$3.0M-60.9%83.2%-2620%$-0.41$-51.1M
Q4 FY25$7.0M—91.4%-866%$-0.32$-44.9M
Q3 FY25$0———$-0.43$-62.1M
Q2 FY25$677K—100%-11351%$-0.41$-55.3M

Forward consensus

5-year forecast · up to 10 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$10.5M$4.3M – $19.6M-$1.60-$1.71 – -$1.479
FY27$17.9M$12.2M – $23.6M-$1.62-$1.76 – -$1.479
FY28$25.0M$9.6M – $74.4M-$1.62-$1.77 – -$1.4310
FY29$162.2M$62.0M – $483.0M-$1.19-$4.23 – -$0.235
FY30$433.2M$165.7M – $1.3B-$0.38-$1.37 – -$0.085

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.6×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.79%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-7.6%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+28.2%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatMid float · 171.5M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today1.1% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β1.705-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.FilingActive offeringA shelf registration (S-3 / S-3ASR / S-1) or prospectus supplement (424B*) was filed in the last 90 days — the company is registered to (or actively) issuing new shares. Dilution risk.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellSep 8Thomas CatinazzoCFO17.7K sh$336KSellSep 8Donald A BergstromPresident8.5K sh$162KSellSep 8Sanjiv PatelCEO48.2K sh$913KSellAug 26Peter RahmerSee remarks4.5K sh$90KSellAug 25Svf Pauling (cayman) Ltd10% owner6.0M sh$116.4MSellAug 17Sanjiv PatelCEO48.2K sh$980KSellAug 14Thomas CatinazzoCFO17.7K sh$350KSellJul 28Donald A BergstromPresident2.2K sh$42KSellJul 28Peter RahmerSee remarks748 sh$14KSellJul 28Thomas CatinazzoCFO1.5K sh$27K
1–10 of 22
+ 12 other (9 awards · 3 exempts) in window

See when $RLAY insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

424B5Prospectus supplement (offering)Aug 6424B5
AI summary

RLAY (RLAY) filed a prospectus supplement (Form 424B5) on 2026-08-06 for an immediate offering of 16,006,569 shares $0.001 per share, raising approximately $212,978,049 . Use of proceeds: general corporate purposes. This is dilutive capital activity happening now, distinct from a shelf registration — new shares will be issued. Investors should assess pricing relative to market and stated use of proceeds to evaluate dilution impact.

8-KMaterial agreementAug 68-K — Item 1.01: Material agreement · Item 2.02: Earnings release
AI summary

RELAY THERAPEUTICS, INC. (RLAY) reported earnings and disclosed a material agreement on 2026-08-06, reporting financial results details in attached press release. The press release notes: mission under the Securities Act of 1933, as amended (the “S. Additional items: Item 1.01. Quarterly earnings are a material disclosure; investors should review the full press release for segment details and management commentary.

8-KCharter amendmentJun 98-K — Item 5.03: Charter amendment · Item 5.07: Shareholder vote
AI summary

Relay Therapeutics (RLAY) held its 2026 Annual Meeting on June 9, 2026, electing Class III directors Douglas Ingram (120.9M for) and Claire Mazumdar (122.9M for) to three-year terms through 2029. Separately, stockholders approved — and Relay immediately filed — a Certificate of Amendment increasing authorized common shares from 300 million to 450 million. The 50% authorized share expansion (approved by a majority of votes cast) was the most material action at the meeting, giving Relay significant additional capacity for future equity raises or acquisitions.

8-KMaterial agreementMay 218-K — Item 1.01: Material agreement
AI summary

Relay Therapeutics, Inc. (RLAY) filed an 8-K on May 20, 2026 disclosing a material definitive agreement (Item 1.01). Relay is a Cambridge, Massachusetts-based clinical-stage precision medicine company focused on protein motion science, listed on Nasdaq. Filed concurrently with Relay's $275M equity offering (424B5), this material agreement may relate to a licensing, collaboration, or acquisition that the equity raise is intended to support; the specific terms and counterparty are not visible in the excerpt.

424B5Prospectus supplement (offering)May 21424B5
AI summary

Relay Therapeutics, Inc. (RLAY) priced a public offering of 22,916,667 shares of common stock at $12.00 per share for gross proceeds of approximately $275 million, per a 424B5 filed May 21, 2026; the underwriting discount is $0.72/share ($16.5M total), yielding net proceeds of ~$258.5M before expenses, with a 30-day overallotment option for 3,437,500 additional shares. The offering price represents a modest discount to the last sale price of $12.20. This is a large dilutive primary equity raise for Relay Therapeutics, likely funding its precision oncology and protein motion drug discovery programs.

424B5Prospectus supplement (offering)May 19424B5
AI summary

Relay Therapeutics, Inc. (RLAY) filed a preliminary prospectus supplement for an underwritten public offering of $175 million of common stock, with a 30-day overallotment option for an additional $26.25 million, led by Jefferies, TD Cowen, Goldman Sachs, and Guggenheim Securities. The last reported sale price on May 15, 2026 was $12.20 per share; final per-share price and share count are not set in this preliminary supplement. This is a dilutive equity raise for a clinical-stage biotech, likely to fund the ReInspire Phase 2 trial of zovegalisib and other pipeline development.

8-KPress release / Reg FDMay 198-K — Item 7.01: Press release / Reg FD · Item 8.01: Other event
AI summary

Relay Therapeutics, Inc. (RLAY) released initial Phase 2 ReInspire trial clinical data for zovegalisib in vascular anomalies via Reg FD press release (Exhibit 99.1) and a slide presentation (Exhibit 99.2) on May 19, 2026, with a live conference call and webcast at 8:00 a.m. ET. This represents a pivotal Phase 2 data readout for zovegalisib in a rare vascular indication, with efficacy and safety results that could define the drug's further development path and materially impact the company's pipeline value.

8-KPress release / Reg FDApr 278-K — Item 7.01: Press release / Reg FD · Item 8.01: Other event
AI summary

RLAY filed an 8-K Item 7.01 (Reg FD) disclosure dated 2026-04-27. Covers: slide presentation to accompany the call, a copy of which is being furnished as Exhibit 99. Reg FD disclosures make material information simultaneously available to all investors; content may include guidance updates, strategic plans, or preliminary results.

+ 13 other (6 13Gs · 2 10-Qs · 2 proxys · 1 earnings 8-K) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Relay Therapeutics, Inc. (RLAY) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcriptseekingalpha.com·14d agoSquarepoint Ops LLC Has $1.74 Million Position in Relay Therapeutics, Inc. $RLAYdefenseworld.net·14d agoVIRGINIA RETIREMENT SYSTEMS ET Al Acquires New Stake in Relay Therapeutics, Inc. $RLAYdefenseworld.net·15d agoRelay Therapeutics, Inc. (RLAY) Presents at Wells Fargo 21st Annual Healthcare Conference Prepared Remarks Transcriptseekingalpha.com·20d agoAllianz Asset Management GmbH Makes New $750,000 Investment in Relay Therapeutics, Inc. $RLAYdefenseworld.net·20d ago

In themes

Explore the broader themes this ticker is being talked about under.

Best PerformersAI Precision Medicine

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$VKTX$MRNA$RARE$NWBO$AURA$ARCT$IBRX$NKTR
Voices on X · last 7 days

No standout posts about $RLAY on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport